JPRN-UMIN000028523已完成未知
Identification of genetic markers that predicts adverse effects of new melanoma therapies - Identification of genetic markers that predicts adverse effects of new melanoma therapies
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 112
研究概览
简要总结
Our analysis showed that no KIR gene was associated with a response to nivolumab. The KIR/KIR-ligand combination did not correlate with a response to nivolumab. KIR genes were not predictive of experiencing adverse events of grade 2 or greater. We conclude that the KIR genotype or KIR/KIR-ligand genotype do not show predictive value in melanoma patients receiving nivolumab.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are followed for less than 3 months after the initiation of the therapy
研究者
相似试验
已完成
不适用
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701LymphomaNCT01057459Alliance for Clinical Trials in Oncology78
已完成
不适用
KIRS-study: expression of inhibitory receptors on polymorphonuclear neutrophils during sepsis in childreBlood poisoning10019815SepsisNL-OMON41281niversitair Medisch Centrum Utrecht60
进行中（未招募）
不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patientsEUCTR2011-006009-85-NLVU University medical center225
已完成
不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patientskidney cancerRenal cell cancer10038364NL-OMON37502Vrije Universiteit Medisch Centrum225
招募中
不适用
A two parts, biomarker study to identify genetic aberrations predictive for response on Everolimus in solid tumors without regular treatment options (CPCT*03)regular therapy refractory cancer10027655NL-OMON40040Antoni van Leeuwenhoek Ziekenhuis80